London, UK (PRWEB) October 11, 2012
During 20042010, biologics recalls have increased to a great extent, of which the recalls for vaccines and immunoglobulins were more frequent than for other drug classes. The underlying causes of recalls varied from serious adverse events, labeling errors and quality defects, to defects that occurred during the manufacturing process. Over the review period, the highest number of biologics recalls occurred in 2010, especially in the infectious diseases and immunodeficiency disorders therapy areas.
In-demand market study Regulatory Intelligence on Biologics Recalls Immunoglobulins and Vaccines are Involved in More Recalls than Other Drug Classes developed by GBI Research has been recently published by Market Publishers Ltd.
Report Details:
Title: Regulatory Intelligence on Biologics Recalls Immunoglobulins and Vaccines are Involved in More Recalls than Other Drug Classes
Published: March, 2012
Pages: 72
Price: US$ 3,500.00
http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/drugs_biotechnology/regulatory_intelligence_on_biologics_recalls_v_immunoglobulins_n_vaccines_are_involved_in_more_recalls_than_other_drug_classes.html
The study provides comprehensive up-to-date coverage of biologics recalls issued or reported with the US Food and Drug Administration (FDA) and its constituent agencies.
Report Scope: